DSM B.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
11 feb 2015 - 07:15
Statutaire naam
DSM B.V.
Titel
DSM reports 2014 results
Bericht
• 2014 sales of €9,181 million
• Organic sales growth 5% in Q4 2014 and 3% for 2014
• Q4 2014 EBITDA €288 million and 2014 EBITDA €1,168 million
• Strong cash from operating activities of €418 million in Q4 2014 (€808 million in 2014)
• Non-cash impairment of €186 million of the caprolactam business (after tax and non-controlling interests) included in exceptional items, leading to a net loss in Q4 2014
• Proposed dividend stable at €1.65 per ordinary share
• DSM will take further actions to improve efficiencies and to reduce costs
• DSM aims to deliver 2015 EBITDA slightly ahead of 2014
Datum laatste update: 23 februari 2026